Relevant conflicts of interest/financial disclosures: Nothing to report.
Defining the Epsilon-Sarcoglycan (SGCE) Gene Phenotypic Signature in Myoclonus-Dystonia: A Reappraisal of Genetic Testing Criteria
Article first published online: 15 MAY 2013
Copyright © 2013 Movement Disorder Society
Volume 28, Issue 6, pages 787–794, June 2013
How to Cite
Carecchio, M., Magliozzi, M., Copetti, M., Ferraris, A., Bernardini, L., Bonetti, M., Defazio, G., Edwards, M. J., Torrente, I., Pellegrini, F., Comi, C., Bhatia, K. P. and Valente, E. M. (2013), Defining the Epsilon-Sarcoglycan (SGCE) Gene Phenotypic Signature in Myoclonus-Dystonia: A Reappraisal of Genetic Testing Criteria. Mov. Disord., 28: 787–794. doi: 10.1002/mds.25506
Full financial disclosures and author roles may be found in the online version of this article.
- Issue published online: 25 JUN 2013
- Article first published online: 15 MAY 2013
- Manuscript Accepted: 9 APR 2013
- Manuscript Revised: 27 MAR 2013
- Manuscript Received: 18 JUL 2012
- Italian Ministry of Health (Ricerca Corrente 2013) and the Dystonia coalition grant
- Department of Health's NIHR Biomedical Research Centres' funding scheme
Additional Supporting Information may be found in the online version of this article.
|mds25506-sup-0001-supptable1.doc||33K||Supplementary Table 1. Diagnostic criteria for myoclonus-dystonia and proposed New Score to predict SGCE mutation positivity.|
|mds25506-sup-0002-suppvideo1.mp4||43272K||Supporting Information Video|
Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.